Citation

ten Ham M. Drug Safety 2003; 26(14): 991-997.

Affiliation

Department of Pharmaceuticals and Medical Technology, Ministry of Public Health, Welfare and Sport, Den Haag, The Netherlands. m.t.ham@minvws.nl

Copyright

(Copyright © 2003, Adis International)

DOI

unavailable

PMID

14583061

Abstract

Pharmaceutical products are not exempt from the practice of counterfeiting. In recent years, many reports have become available demonstrating the presence of fake medicines on the market. Several studies have demonstrated that they are quite often of bad quality. It is estimated that 5% of all world trade in branded goods is counterfeit, leading to huge financial losses for the pharmaceutical industry. But much more important, from a public health point of view, is that history has shown that such products may lead to a great health risk. The essence of counterfeit products and the reason they are so dangerous is the complete absence of quality control, since they are often indistinguishable from the genuine product. The existence of counterfeit drugs has long been ignored both by the pharmaceutical industry and by drug regulatory authorities. At present initiatives are being taken, nationally and internationally, to curb counterfeiting. It is now realised that a strong regulatory agency is essential, but the initiatives can only be successful if all parties concerned actively co-operate.

Language: en